Research Grade
Reaktivität: Human respiratory syncytial virus A
Wirt: Humanized
Chimeric
unconjugated
Recombinant Antibody
Beschränkungen
Nur für Forschungszwecke einsetzbar
Buffer
PBS pH 7.5
Lagerung
-80 °C
Informationen zur Lagerung
store at -80°C
Target
RSV (Palivizumab Biosimilar)
Substanzklasse
Biosimilar
Hintergrund
MEDI-493, Synagis Palivizumab is a humanized monoclonal antibody of isotype IgG1k produced by recombinant DNA technology. It targets the epitope in the A antigenic site of the respiratory syncytial virus (RSV) F protein.